New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:35 EDTHSP, CBSTHospira granted tentative approval for generic daptomycin
Hospira (HSP) was granted tentative approval for generic daptomycin, according to a post to the FDA's website dated June 16. Daptomycin is an antibiotic used in the treatment of infections caused by Gram-positive organisms that is sold under the trade name Cubicin by Cubist Pharmaceuticals (CBST). Reference Link
News For HSP;CBST From The Last 14 Days
Check below for free stories on HSP;CBST the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2014
11:26 EDTCBSTAmerican Society for Microbiology to hold a conference
Subscribe for More Information
August 31, 2014
14:04 EDTCBSTWorldwide Business Research to hold a conference
Subscribe for More Information
August 22, 2014
07:31 EDTCBSTCubist annouces EMA acceptance of ceftolozane, tazobactam MAA
Cubist announced that the European Medicines Agency has accepted for review the company’s Marketing Authorization Application for its investigational antibiotic ceftolozane, tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections, with a decision from the European Commission expected during 1H15. The MAA submission is based on positive data from two pivotal Phase 3 clinical trials of ceftolozane, tazobactam in complicated urinary tract infections and complicated intra-abdominal infections. These studies met both the EMA and U.S. Food and Drug Administration specified primary endpoints. Results of the secondary analyses were consistent with and supportive of the primary outcomes.
August 20, 2014
11:50 EDTHSPJudge rules generic Precedex FDA approval postponed, WSJ says
Subscribe for More Information
August 19, 2014
09:09 EDTHSPHospira discloses it filed lawsuit against FDA regarding Precedex
Subscribe for More Information
09:08 EDTHSPHospira backs FY14 EPS $2.30-$2.50, consensus $2.43
August 18, 2014
11:41 EDTCBST, HSPCubist rises after report sparks takeover interest speculation
Subscribe for More Information
09:43 EDTCBSTCubist may receive takeover interest, Bloomberg reports
Cubist Pharmaceuticals' (CBST) focus on bacterial infections could attract takeover interest, Bloomberg reports in its Real M&A column. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use